NCT00337467View on ClinicalTrials.gov

Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression

PHASE3CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2009

Conditions
Human Immunodeficiency Virus (HIV) Infections
Interventions
DRUG

Atazanavir + Ritonavir

Capsules, Oral, ATV 300mg + RTV 100mg, once daily, 96 weeks

Trial Locations (7)

14004

Local Institution, Córdoba

28007

Local Institution, Madrid

28034

Local Institution, Madrid

28040

Local Institution, Madrid

28041

Local Institution, Madrid

28046

Local Institution, Madrid

29010

Local Institution, Málaga

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00337467 - Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression | Biotech Hunter | Biotech Hunter